The application of mathematical modelling to the design of bispecific monoclonal antibodies

References

• Groenendijk FH, Bernards R. Drug resistance to targeted therapies: Déjà vu all over again. Mol Oncol 2014; 12:1-17; PMID:24910388; http://dx.doi.org/:10.1016/j.molonc.2014.05.004.
   Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26; PMID:24060863; http://dx.doi.org/10.1038/nrc3599
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre D V, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 2015; 7:37-41 PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816.
   Google Scholar
• Croasdale R, Wartha K, Schanzer JM, Kuenkele K-P, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IBJK, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele K-P, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, et al. A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. J Biol Chem 2014; 289:18693-706; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
   PubMed Web of Science ®Google Scholar
• Emanuel SL, Engle LJ, Chao G, Zhu R-R, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48; PMID:21099371; http://dx.doi.org/10.4161/mabs.3.1.14168
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-72; PMID:15757893; http://dx.doi.org/10.1074/jbc.M500815200
   PubMed Web of Science ®Google Scholar
• Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992; 52:4157-67; PMID:1638531
   PubMed Web of Science ®Google Scholar
• Müller KM, Arndt KM, Plückthun A. Model and simulation of multivalent binding to fixed ligands. Anal Biochem 1998; 261:149-58; PMID:9716417; http://dx.doi.org/10.1006/abio.1998.2725
   PubMed Web of Science ®Google Scholar
• Doldán-Martelli V, Guantes R, Míguez DG. A mathematical model for the rational design of chimeric ligands in selective drug therapies. CPT pharmacometrics Syst Pharmacol 2013; 2:e26; PMID:23887616; http://dx.doi.org/10.1038/psp.2013.2
   Google Scholar
• Harms BD, Kearns JD, Iadevaia S, Lugovskoy A. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 2014; 65:95-104; PMID:23872324; http://dx.doi.org/10.1016/j.ymeth.2013.07.017
   PubMed Web of Science ®Google Scholar
• Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM. Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J Pharmacokinet Pharmacodyn 2015; 42(1):1-18; PMID:25559227; http://dx.doi.org/10.1007/s10928-014-9401-1
   PubMed Web of Science ®Google Scholar
• Harms BD, Kearns JD, Su S V, Kohli N, Nielsen UB, Schoeberl B. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Methods Enzymol 2012; 502:67-87; PMID:22208982; http://dx.doi.org/10.1016/B978-0-12-416039-2.00004-5
   PubMed Web of Science ®Google Scholar
• Arteaga C. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-30; PMID:12648471; http://dx.doi.org/10.1016/S0014-4827(02)00104-0
   PubMed Web of Science ®Google Scholar
• Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001; 18:95-108; PMID:11566601; http://dx.doi.org/10.1016/S1389-0344(01)00090-9
   PubMedGoogle Scholar
• Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 2012; 62:217-23; PMID:23223907; http://dx.doi.org/10.1007/s00262-012-1369-3
   PubMed Web of Science ®Google Scholar
• Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M, Coleman RE. Original article Phase I open study of the effects of ascending doses of the cytotoxic. Ann Oncol 2000; 11:735-41; PMID:10942064; http://dx.doi.org/10.1023/A:1008349300781
   PubMed Web of Science ®Google Scholar
• Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406-13; PMID:11466696; http://dx.doi.org/10.1002/1097-0142(20010715)92:2%3c406::AID-CNCR1336%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Onda M, Willingham M, Wang Q -C, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I. Inhibition of TNF- Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. J Immunol 2000; 165:7150-6; PMID:11120846; http://dx.doi.org/10.4049/jimmunol.165.12.7150
   PubMed Web of Science ®Google Scholar
• Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 1999; 163:6072-7; PMID:10570296
   PubMed Web of Science ®Google Scholar
• Batelli MG, Buonamici L, Politio L, Bolognesi A, Stirpe F. Hepatotoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum. Virchows Arch 1996; 427:529-35; PMID:8624583
   PubMed Web of Science ®Google Scholar
• Mosure KW, Henderson a J, Klunk LJ, Knipe JO. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 1997; 40:251-8; PMID:9219510; http://dx.doi.org/10.1007/s002800050655
   PubMed Web of Science ®Google Scholar
• Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. 2003; 55:171-97; PMID:12564976
   PubMedGoogle Scholar
• Chittenden TD, Setiady YY, Park PU, Ponte JF, Dong L, Skaletskaya A, Carrigan CN, Villaluz AA, Pinkas J, Lutz RJ, Lambert JM. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Res 2013; 73: Abstract nr 5467; http://dx.doi.org/10.1158/1538-7445.AM2013-5467
   Web of Science ®Google Scholar
• Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8(6):1095-111; PMID:25087573; http://dx.doi.org/10.1016/j.molonc.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Krippendorff B-F, Oyarzún D a, Huisinga W. Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 2012; 39:125-39; PMID:22399130; http://dx.doi.org/10.1007/s10928-012-9243-7
   PubMed Web of Science ®Google Scholar
• Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19:89-99; PMID:21178280; http://dx.doi.org/10.3233/HAB-2010-0232.
   PubMedGoogle Scholar